CRXM Stock - Gene Biotherapeutics, Inc.
Unlock GoAI Insights for CRXM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,816 | $-58,175 | $-63,201 | $-66,087 | $-20,026 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-1,262,000 | $-837,000 | $-513,000 | $-2,076,000 | $-2,841,000 |
| Net Income | $-518,000 | $866,675 | $-435,000 | $-1,894,000 | $-2,918,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.02 | $0.06 | $-0.03 | $-0.13 | $-0.22 |
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.
Visit WebsiteEarnings History & Surprises
CRXMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2021 | Apr 23, 2021 | — | — | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.02 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.02 | — | — |
Q2 2020 | Jun 30, 2020 | — | $0.00 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.01 | — | — |
Q4 2019 | Dec 31, 2019 | — | $0.10 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.01 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.02 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.02 | — | — |
Q1 2017 | Mar 31, 2017 | — | $-0.04 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.06 | — | — |
Q4 2016 | Oct 27, 2016 | — | $-0.14 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.05 | — | — |
Q1 2016 | Mar 31, 2016 | — | $-0.03 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.04 | — | — |
Q3 2015 | Sep 30, 2015 | — | $-0.09 | — | — |
Q2 2015 | Jun 18, 2015 | — | $-0.05 | — | — |
Q1 2015 | Mar 31, 2015 | — | $-0.05 | — | — |
Q4 2014 | Nov 20, 2014 | — | $-0.06 | — | — |
Q3 2014 | Sep 30, 2014 | — | $-0.12 | — | — |
Latest News
Frequently Asked Questions about CRXM
What is CRXM's current stock price?
What is the analyst price target for CRXM?
What sector is Gene Biotherapeutics, Inc. in?
What is CRXM's market cap?
Does CRXM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CRXM for comparison